A Long-Term Follow-Up Study in Subjects Who Received vMCO-I Administered Via Intravitreal Injection
Launched by NANOSCOPE THERAPEUTICS INC. · Jun 19, 2023
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The observational study population comprises of individuals who received an Adeno-Associated Viral Vector Serotype 2 Containing the Multi-Characteristic Opsin Gene (vMCO-I) Administered Via Intravitreal Injection in a parent study.
Enrolled subjects will undergo safety and efficacy assessments for up to 5 years from the vMCO-I administration. At the visits, subjects will have safety and efficacy evaluations. Subjects will have a final visit at 60 months post study drug administration.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The subject population includes subjects who received an Adeno-Associated Viral Vector Serotype 2 Containing the Multi-Characteristic Opsin Gene (vMCO-I), administered via intravitreal injection in a parent study.
- Exclusion Criteria:
- • Subjects who will not consent for study.
About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics Inc. is a pioneering biotechnology company focused on developing innovative gene therapies to address retinal diseases and restore vision. With a commitment to advancing therapeutic solutions, Nanoscope leverages cutting-edge technologies and a robust scientific foundation to create transformative treatments for patients with unmet medical needs. The company’s research-driven approach aims to harness the power of gene editing and novel delivery systems, positioning Nanoscope as a leader in the field of ocular therapeutics. Through rigorous clinical trials and a dedication to patient outcomes, Nanoscope Therapeutics is dedicated to improving the quality of life for individuals suffering from debilitating visual impairments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cuttack, Odisha, India
Patients applied
Trial Officials
Samarendra Mohanty
Study Director
Nanoscope Therapeutics Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported